We are live on ! Find out more
IMMU

Immunomedics Inc
IMMU

Delisted

IMMU was delisted on the 22nd of October, 2020.

408 hedge funds and large institutions have $17B invested in Immunomedics Inc in 2020 Q3 according to their latest regulatory filings, with 160 funds opening new positions, 87 increasing their positions, 134 reducing their positions, and 64 closing their positions.

New
Increased
Maintained
Reduced
Closed

325% more funds holding in top 10

Funds holding in top 10: 1668 (+52)

150% more first-time investments, than exits

New positions opened: 160 | Existing positions closed: 64

131% more capital invested

Capital invested by funds: $7.38B → $17B (+$9.64B)

49% more call options, than puts

Call options by funds: $389M | Put options by funds: $262M

30% more funds holding

Funds holding: 313408 (+95)

35% less repeat investments, than reductions

Existing positions increased: 87 | Existing positions reduced: 134

Holders
408
Holders Change
+95
Holders Change %
+30.35%
% of All Funds
8.23%
Holding in Top 10
68
Holding in Top 10 Change
+52
Holding in Top 10 Change %
+325%
% of All Funds
1.37%
New
160
Increased
87
Reduced
134
Closed
64
Calls
$389M
Puts
$262M
Net Calls
+$127M
Net Calls Change
+$11.9M
Name Holding Trade Value Shares
Change
Change in
Stake
RSCM
26
Rock Springs Capital Management
Maryland
$135M -$4.56M -90,179 -5%
FLAM
27
First Light Asset Management
Minnesota
$134M -$4.59M -90,860 -5%
D.E. Shaw & Co
28
D.E. Shaw & Co
New York
$129M +$48.6M +960,173 +173%
N
29
Nuveen
North Carolina
$123M +$18.9M +374,181 +35%
AAM
30
Alpine Associates Management
Florida
$120M +$71.5M +1,414,515 New
UOC
31
UBS O'Connor
Illinois
$118M +$70.4M +1,392,226 New
TCM
32
TimesSquare Capital Management
New York
$116M -$22.4M -443,400 -24%
PHS
33
PFM Health Sciences
California
$114M -$92.8M -1,835,404 -58%
T. Rowe Price Associates
34
T. Rowe Price Associates
Maryland
$114M -$280M -5,542,557 -81%
PAMU
35
Pictet Asset Management (UK)
United Kingdom
$105M -$56.8M -1,122,931 -48%
Adage Capital Partners
36
Adage Capital Partners
Massachusetts
$102M +$60.7M +1,200,000 New
Allianz Asset Management
37
Allianz Asset Management
Germany
$98.1M -$19.1M -377,248 -25%
JP Morgan Chase
38
JP Morgan Chase
New York
$96.8M -$14.4M -285,241 -20%
Bank of America
39
Bank of America
North Carolina
$91.5M +$12.8M +253,396 +31%
TCA
40
Taconic Capital Advisors
New York
$91.4M +$54.4M +1,075,000 New
MF
41
Magnetar Financial
Illinois
$89.5M +$53.2M +1,052,070 New
BCM
42
Beryl Capital Management
California
$89M +$52.9M +1,046,632 New
Northern Trust
43
Northern Trust
Illinois
$88.1M -$1.51M -29,955 -3%
OP
44
Omni Partners
United Kingdom
$82.9M +$49.3M +975,434 New
Balyasny Asset Management
45
Balyasny Asset Management
Illinois
$80.9M +$48.1M +951,165 New
Fidelity International
46
Fidelity International
Bermuda
$80.4M +$47.8M +945,509 +225,658%
Charles Schwab
47
Charles Schwab
California
$78.3M -$5.28M -104,329 -10%
Bank of New York Mellon
48
Bank of New York Mellon
New York
$78.1M +$4.25M +83,955 +10%
PA
49
Perceptive Advisors
New York
$77.6M +$27.8M +550,000 +152%
American Century Companies
50
American Century Companies
Missouri
$76.6M -$94.2M -1,863,220 -67%

IMMU Hedge Fund Activity: Q3 2020 in Review

408 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Immunomedics Inc (IMMU) for Q3 2020, worth a combined $17B — up 131% from $7.38B a quarter earlier.

Buyers outnumbered sellers: 160 funds opened new IMMU positions and 64 closed out — a net gain of 96 holders — while 87 added to existing stakes and 134 trimmed.

The largest buyer was HBK Investments, opening a new position worth an estimated $329M. The largest seller was Fidelity Investments, cutting an estimated $486M.

  • 408 institutional investors held Immunomedics Inc (IMMU) as of Q3 2020, up from 313 in Q2 2020.
  • Funds reported $17B of Immunomedics Inc stock for Q3 2020, up 131% quarter-over-quarter.
  • 160 funds opened new Immunomedics Inc positions in Q3 2020 and 64 closed out, a net change of +96 holders.
  • The largest Immunomedics Inc buyer in Q3 2020 was HBK Investments, an estimated $329M added.
  • The largest Immunomedics Inc seller in Q3 2020 was Fidelity Investments, an estimated $486M sold.

Based on aggregated 13F filings for Q3 2020.